|
Viapro Clinical Trials Viapro™ has conducted a randomized, double-blind, placebo-controlled clinical study led by a board-certified urologist on efficacy and safety of Viapro™ (GL49). 47 subjects with mild to moderate erectile dysfunction (ED) were randomized to receive placebo or Viapro™ for one month. Efficacy was assessed by standardized questionnaires and diary after each sexual activity. Safety was assessed by subject report on adverse events and blood tests.  The study results show that Viapro™: Significantly increased erectile function (as shown by IIEF (International Index of Erectile Function) EF (Erectile Function) domain score and Question 3 and 4 scores): EF domain score increase of 7.65 with Viapro™ (vs a decrease of 1.74 with placebo, P<0.0001) and significant increase of Question 3 (ability to obtain an erection) and Question 4 (ability to maintain an erection) scores (P<0.0001) Significantly increased firmness and duration of erections: over 91% of subjects were able to penetrate successfully; over 85% of subjects were able to complete intercourse successfully; 83% had increased firmness of erections; 75% had increased duration of erections Made clinically significant improvement on 80% of subjects with ED (defined as EF increase>=5) (P<0.0001 vs placebo) Helped 62.5% of subjects with erectile dysfunction (ED) regain normal sexual function (clinically defined as EF>=26) after taking Viapro™ for one month (P<0.0001 vs placebo) Significantly increased sexual desire in subjects with regular or low sex drive: IIEF Sexual Desire domain score increase of 1.46 with Viapro™ (vs a decrease of 0.46 with placebo, P<0.0001); more than 70% of subjects reported increase in sex drive and intercourse frequency with Viapro™ (vs 13.04% and 8.7% with placebo, respectively, P<0.0001); 71% of subject with self-reported low sex drive had significant increase in sexual desire with Viapro™ (vs 0% with placebo) Lasted 24-48 hours with one dose Significantly improved sexual relationship, self confidence and quality of life: IIEF Overall Satisfaction domain score increase of 2.00 with Viapro™ (vs a decrease of 0.39 with placebo, P<0.0001); more than 75% of subjects reported improvement in sex life; 67% reported improvement in sexual relationship; 79% reported improvement in confidence of sexual ability; 79% reported improvement in self-esteem; 75% reported improvement in quality of life; 75% of subjects and partners reported feeling happier after the study Showed no serious side effects: only mild and temporary side effects were reported by a small percentage of subjects These results suggest that Viapro™ may be effective and safe for improving male erectile function and sexual desire.      An open pilot clinical study was conducted by a laboratory to test the efficacy and safety of Viapro™. 101 male subjects with normal or impaired erectile function were given Viapro™ for one week and reported improvement on:
|
Shopping Basket
----------------------------
| Total Items: | 0 |
| Sub Total: | £0.00 |
| Delivery: | £0 |
| ---------------------------- | |
| Grand Total: | £0.00 |
 |
 |
 |
 |